Bioceltix (WAR:BCX) Total Operating Expense: zł14.69 Mil (TTM As of Mar. 2026)


WAR:BCX Bioceltix SA WAR:BCX
27 GF Score
Price zł89.70
! 1 Warning Sign
View Full Analysis

What is Bioceltix Total Operating Expense?

Bioceltix WAR:BCX -0.77% 27 Total Operating Expense is zł14.69 Mil as of Mar. 2026. GuruFocus rates WAR:BCX with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Bioceltix's Total Operating Expense for the three months ended in Mar. 2026 was zł4.70 Mil. Bioceltix's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was zł14.69 Mil.

Bioceltix Total Operating Expense Related Terms

Bioceltix Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Bioceltix's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioceltix Total Operating Expense Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 3.55 8.26 12.98 13.30 13.12

Bioceltix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 3.20 3.91 2.88 4.70
WAR:BCX
27GF Score
Bioceltix SA WAR:BCX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioceltix Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł14.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of zł14.69 Mil mean?
Bioceltix (WAR:BCX) has a Total Operating Expense of zł14.69 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Bioceltix and its competitors.
Is Bioceltix's Total Operating Expense too high?
Bioceltix's current Total Operating Expense is zł14.69 Mil. Overall, Bioceltix has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Bioceltix's Total Operating Expense compare to VRTX and REGN?
Bioceltix's Total Operating Expense of zł14.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Bioceltix and its competitors. Bioceltix's current Total Operating Expense is zł14.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioceltix stock overvalued right now?
Bioceltix (WAR:BCX) has a current Total Operating Expense of zł14.69 Mil. The current Total Operating Expense is zł14.69 Mil. Bioceltix's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Bioceltix (WAR:BCX), the current Total Operating Expense is zł14.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioceltix Business Description

Address Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
27GF Score

Get the complete analysis for WAR:BCX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł89.70
Price